RELMADA THERAPEUTICS, INC. — Director's Dealing 2015

Nov 16, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2015-11-12

Reporting Person: Kelly Paul Edward (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$3.45	2025-11-12	Common Stock (25765)		Direct

Footnotes

F1: Options granted on November 12, 2015 to purchase an aggregate of 25,765 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.